Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at Precision Medicine World Conference
Expert panels to examine collaborative solutions in biomarker testing
June 16, 2022
June 16, 2022
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that its Senior Vice President of Clinical Development Kat Kwiatkowski, PhD, will participate in two panel discussions at the Precision Medicine World Conference (PMWC) 2022, being held live from June 28-30 in Santa Clara, CA.
Details of the panels are as follows:
Title: Dismantling Barriers to Biomarker Testing Through Collaboration
- Time: Tuesday, June 28 at 9:00 AM pacific time
- Participants: Omar Perez, PhD, Head of Medical Diagnostics, U.S. Medical Affairs Oncology, AstraZeneca; Kat Kwiatkowski, PhD Senior Vice President of Clinical Development, Strata Oncology; Jenn Higgins, Vice President, Public Affairs, Guardant Health; Nikki Martin, Director, Precision Medicine Initiatives, LUNGevity Foundation; Laura J. van’t Veer, PhD, Professor of Laboratory Medicine, University of California San Francisco
Title: Immuno-oncology Biomarkers for Predicting Drug Efficacy
- Time: Tuesday, June 28 at 11:30 AM pacific time
- Participants: Ronnie Andrews, President and CEO, OncoCyte; Kat Kwiatkowski, PhD Senior Vice President of Clinical Development, Strata Oncology; Paul Billings, MD, PhD, FACP, FACMGG, Chief Executive Officer and Director, Biological Dynamics
Recordings of the panels will be available afterwards. For more information, visit https://www.pmwcintl.com.